FDA to Pharma: Forget About Tweets! But You Can Host Discussion Forums About Branded Rx Products, Sorta, & Kinda Correct Misinformation

FDA has just released two guidance documents that finally address major issues discussed at the November 2009 public hearing:How to present both benefit and risk information within a “promotion” of their FDA-regulated medical products on electronic/digital platforms that are associated with character space limitations, specifically on through social media such as Twitter and through online paid search (e.g., “sponsored links” on search engines such as Google and Yahoo); and How to respond to misinformation related to a firm’s own FDA-approved or -cleared products when that information is created or disseminated by independent third parties on the Internet or through social media, regardless of whether that misinformation appears on a firm’s own forum or an independent third-party forum or website. You can find these documents here and here.Don't bother reading the first one about posting promotions via Twitter and other venues with space limitations. FDA is NOT approving the "one-click rule," which started this whole mishegoss about regulating pharma marketing via social media (see Death of the One-Click "Rule" or "Received Precedent" or Whatever!). FDA essentially says, too bad, you have to include everything -- benefits AND major side effects -- in the space allotted. Plus, you also have to link to more detailed information about side effects.Essentially, unless you do reminder ads (like Novo Nordisk's Branded (Levemir) Sl...
Source: Pharma Marketing Blog - Category: Pharma Commentators Tags: #fdasm Guidance guidelines social media Wikipedia Source Type: blogs